CEACAM1 as a Multi-Purpose Target for Cancer Immunotherapy
Matthew Dankner(McGill University Health Centre), Scott D. Gray‐Owen(University of Toronto), Yu‐Hwa Huang(Brigham and Women's Hospital), Richard S. Blumberg(Brigham and Women's Hospital), Nicole Beauchemin(McGill University Health Centre)
Cited by 118Open Access
Abstract
CEACAM1 is an extensively studied cell surface molecule with established functions in multiple cancer types, as well as in various compartments of the immune system. Due to its multi-faceted role as a recently appreciated immune checkpoint inhibitor and tumor marker, CEACAM1 is an attractive target for cancer immunotherapy. Herein, we highlight CEACAM1's function in various immune compartments and cancer types, including in the context of metastatic disease. This review outlines CEACAM1's role as a therapeutic target for cancer treatment in light of these properties.
Related Papers
No related papers found
Powered by citation graph analysis